Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 4 April 2017, 08:56 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Smell Identification Test UPSIT Series in Japan

TOKYO, Apr 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that the smell identification test "UPSIT Series" will be launched today for sale to health insurance pharmacies and local governments in Japan. The UPSIT Series was developed by Sensonics International. Eisai has obtained exclusive rights to market the test in Japan, and has modified it for the Japanese market.

The UPSIT Series' 4-Item Pocket Smell Test is a multiple-choice test comprised of four microencapsulated odorant strips attached to a thick sheet of paper. The scents are released by lightly scratching the strips with a cotton swab or other tool, after which the person taking the test must attempt to select the correct name of the scent from four options that are provided. In this way, smell identification ability can be determined in approximately 3 minutes.

The sense of smell is one of the important senses for detecting hazards in daily life, such as rotten food, poor hygiene, gas leakage, and fires. Olfactory function, which includes the ability to identify smells (identification) and to detect a faint smell (detection), is influenced by age, physical condition, memory, and psychological state. Persons are often unaware the changes in the ability to identify smells, subjectively. The UPSIT Series, which objectively measures smell identification ability, makes it possible to detect and track changes in physical condition and psychological state.

This test will most likely be used in counseling sessions, such as during health consultations or health promotion events held by health insurance pharmacies or local governments. Should the person taking the test make any mistakes, it may be recommended that they undertake a review of their lifestyle, including sleep, exercise, dietary and smoking habits, under the guidance of a pharmacist or other relevant person. Alternatively, a visit to an otolaryngologist or a primary care physician may be recommended. It is important to note that the UPSIT Series is not an alternative for proper medical examinations and diagnosis by qualified medical professionals.

Scents are made up of multiple chemical substances. The roof of the nasal cavity contains 5 million olfactory receptor cells, each of which reacts to certain chemical substances. These cells work in concert to transmit smell information to the brain. The transmitted information is then integrated with information stored in the brain, including learned information, making it possible to identify "a certain smell".

As one part of the hhc solutions business, Eisai has been engaged for many years in activities for "creating communities where senior citizens can live in peace of mind". In carrying out these activities, Eisai has identified real world needs and issues, also called "clinical questions". By providing solutions to these clinical questions, in cooperation with stakeholders including local governments, medical institutions and pharmacies, Eisai seeks to make further contributions to support health promotion and health management of senior citizens.

About smell identification test UPSIT Series

The UPSIT Series' 4-Item Pocket Smell Test is a multiple-choice test comprised of a four microencapsulated odorant strips attached to a thick sheet of perforated paper. The scents are released by lightly scratching the strips with a cotton swab or other tool, after which the person taking the test must attempt to select the correct scent name from four options. In this way, smell identification ability can be confirmed in approximately 3 minutes. Please note that UPSIT is not medicine or a medical device, and is not an alternative for proper medical examinations and diagnosis by qualified medical professionals. The UPSIT was developed by Richard L. Doty, professor and director the Smell and Taste Center within the Department of Otorhinolaryngology, University of Pennsylvania. Professor Doty also founded Sensonics. Inc. in 1982, and has markeded the UPSIT under the trade name Smell Identification Test worldwide since that time. Multiple products are being developed with different numbers and types of scents.

The Pocket Smell Test contains a set of four scents for the person being tested to identify, including cool scents (minty etc.), sweet scents (strawberry etc.) and unpleasant scents (gas etc.). There are two versions of the 4-Item Pocket Smell Test available, both of which make use of four different scents.

About Sensonics International

Sensonics International, whose headquarters are located in Haddon Heights, NJ, USA, was founded in 1982 and is the largest manufacturer and distributor of smell and taste tests in the world. In addition to marketing a range of smell and taste testing products, it provides industrial and medical consulting services, including the training of organoleptic panels for the food, flavor and fragrance industries, product evaluation, screening of smell function of workpalce employees, and a host of other chemosensation-related activities. Its tests have been administered to over a million people world wide and its flagship test, the UPSIT, has been translated into 30 different langauges.

About smells

Olfactory function, which includes the ability to identify smells (identification) and to detect a faint smell (detection), and detect is influenced by age, physical condition, memory, and psychological state. Since changes in olfactory ability are seldom reported as a subjective symptom, objective confirmation is neccessary. The roof of the nasal cavity is said to have 5 million olfactory cells. Each olfactory cell has one type of receptor, which binds with chemical substances of a matching affinity. A scent is made up of multiple chemical substances, and the bound receptors assemble this information, and transmit it to the brain. There, it is integrated with information stored in the brain, and identifed as "a certain smell". Olfactory disorders are divided into: Respiratory Dysosmia, where scents do not reach the olfactory cells, Olfactory Mucosa Dysosmia, where the olfactory cells and olfactory nerves are damaged, Combined Dysosmia, a combination of the aforementioned, and Central Dysosmia, where the olfactory center or surrounding pathways are damaged.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Apr 4, 2017 08:56 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 20, 2018 17:50 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
Apr 19, 2018 11:07 HKT/SGT
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
Apr 13, 2018 13:22 HKT/SGT
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
Apr 2, 2018 12:44 HKT/SGT
Eisai Submits Supplemental New Drug Application to U.S. FDA
Mar 28, 2018 18:33 HKT/SGT
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
Mar 23, 2018 14:41 HKT/SGT
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Mar 23, 2018 13:40 HKT/SGT
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: